[go: up one dir, main page]

WO2001085709A3 - New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them - Google Patents

New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2001085709A3
WO2001085709A3 PCT/IB2001/000737 IB0100737W WO0185709A3 WO 2001085709 A3 WO2001085709 A3 WO 2001085709A3 IB 0100737 W IB0100737 W IB 0100737W WO 0185709 A3 WO0185709 A3 WO 0185709A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
andrographolide
new compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000737
Other languages
French (fr)
Other versions
WO2001085709A2 (en
Inventor
Srinivas Nanduri
Sriram Rajagopal
Venkateswarlu Akella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Research Foundation
Original Assignee
Dr Reddys Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Research Foundation filed Critical Dr Reddys Research Foundation
Priority to AU2001256568A priority Critical patent/AU2001256568A1/en
Publication of WO2001085709A2 publication Critical patent/WO2001085709A2/en
Publication of WO2001085709A3 publication Critical patent/WO2001085709A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I). The andrographolide derivatives represented by general formula (I) of the present invention are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis and other cardiovascular disorders, antiviral, antimalarial, antibacterial, hepatoprotective, immunomodulating agents and for treatment of metabolic disorders.
PCT/IB2001/000737 2000-05-05 2001-05-02 New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them Ceased WO2001085709A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001256568A AU2001256568A1 (en) 2000-05-05 2001-05-02 New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN353/MAS/2000 2000-05-05
IN353MA2000 2000-06-08
IN435/MAS/2000 2000-06-08
IN435MA2000 2000-06-08

Publications (2)

Publication Number Publication Date
WO2001085709A2 WO2001085709A2 (en) 2001-11-15
WO2001085709A3 true WO2001085709A3 (en) 2002-05-30

Family

ID=26324891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000737 Ceased WO2001085709A2 (en) 2000-05-05 2001-05-02 New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them

Country Status (2)

Country Link
AU (1) AU2001256568A1 (en)
WO (1) WO2001085709A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106800551A (en) * 2015-11-26 2017-06-06 南京明德新药研发股份有限公司 Andrographolide changes structure compound
US10717720B2 (en) 2015-11-26 2020-07-21 Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. Modified compound of andrographolide

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902359B2 (en) 2006-12-11 2011-03-08 Hutchison Medipharma Enterprises Limited Decahydronaphthalene compounds
CN101591686B (en) * 2009-06-23 2011-08-31 南京农业大学 Method for preparing andrographolide esterfied derivatives through biocatalysis
CN103145665B (en) * 2012-04-12 2014-12-31 江西青峰药业有限公司 17-hydro-9-dehydro-14,17-cyclo-andrographolide-19-sulphate and its preparation method and use in drug preparation
CN105541766B (en) * 2015-12-16 2018-08-24 四川理工学院 The andrographolidume derivative of a kind of sulfur-bearing, its pharmaceutical composition, synthetic method and purposes
CN108484543B (en) * 2018-03-23 2020-11-03 海南长春花药业有限公司 Preparation method of potassium dehydroandrographolide succinate or potassium dehydroandrographolide succinate
CN109912583A (en) * 2019-04-03 2019-06-21 四川轻化工大学 Sulfur-containing andrographolide derivatives cyclized at 3, 19-position, pharmaceutical composition, synthetic method and application thereof
CN112645937B (en) * 2020-12-28 2022-05-31 深圳湾实验室 Azaspirocycle, polycyclic andrographolide compound and preparation method thereof, pharmaceutical composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388124A (en) * 1986-09-30 1988-04-19 Toyo Jozo Co Ltd antitumor agent
WO1996017605A1 (en) * 1994-12-06 1996-06-13 Paracelsian, Inc. Use of andrographolide compounds to treat or prevent pathogenicity of diseases
WO1998030213A2 (en) * 1997-01-08 1998-07-16 Paracelsian, Inc. Use of the ah receptor and ah receptor ligands to treat or prevent the cytopathicity of viral infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388124A (en) * 1986-09-30 1988-04-19 Toyo Jozo Co Ltd antitumor agent
WO1996017605A1 (en) * 1994-12-06 1996-06-13 Paracelsian, Inc. Use of andrographolide compounds to treat or prevent pathogenicity of diseases
WO1998030213A2 (en) * 1997-01-08 1998-07-16 Paracelsian, Inc. Use of the ah receptor and ah receptor ligands to treat or prevent the cytopathicity of viral infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU XUE-GAO ET AL: "ANTIFERTILITY EFFECT OF DEHYDROANDROGRAPHOLIDE DERIVATIVES ON MICE AND RATS", ADVANCES IN CONTRACEPTIVE DELIVERY SYSTEMS, REPRODUCTIVE HEALTH CENTER, KAIWAH ISLAND, SC, US, vol. 111, no. 4, 1987, pages 329 - 336, XP000568141, ISSN: 1012-8689 *
TAKAKUNI MATSUDA ET AL: "CELL DIFFERENTIATION-INDUCING DITERPENES FROM ANDROGRAPHIS PANICULATA NEES", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 42, no. 6, 1 June 1994 (1994-06-01), pages 1216 - 1225, XP000567717, ISSN: 0009-2363 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106800551A (en) * 2015-11-26 2017-06-06 南京明德新药研发股份有限公司 Andrographolide changes structure compound
US10717720B2 (en) 2015-11-26 2020-07-21 Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. Modified compound of andrographolide

Also Published As

Publication number Publication date
AU2001256568A1 (en) 2001-11-20
WO2001085709A2 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
MXPA02007513A (en) Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them.
IL148103A0 (en) Novel dicarboxylic acid derivatives with pharmaceutical properties
WO2001019776A3 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
CA2374247A1 (en) Heterocyclic derivatives useful as anticancer agents
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
CA2398620A1 (en) Pyrazine derivatives, pharmaceutical compositions containing them, and intermediates therefor
IL159772A0 (en) Taxol enhancer compounds
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
ATE264337T1 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
MY146279A (en) Compounds affecting glucokinase
HUT62893A (en) Process for producing substituted pyrimidine derivatives and pharmaceutical compositions comprising such compounds as active ingredient
WO2002051819A3 (en) Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
WO2001085709A3 (en) New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them
CA2469592A1 (en) Hiv integrase inhibitors
IL155657A (en) Acylaminoalkyl-substituted benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions comprising them
NO20060650L (en) Quinazoline derivatives as angiogenesis inhibitors
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
CA2331297A1 (en) Hygromycin a derivatives
SG146627A1 (en) Imidazole derivatives
DE60234024D1 (en) NEW RETINOID DERIVATIVES AND A PHARMACEUTICAL ANTI-CANCER COMPOSITION CONTAINING THESE COMPOUNDS
WO2001007418A3 (en) Ceramide analogs, process for their preparation and their use as antitumor agents
IL159521A0 (en) Tricyclic pyridines for use in treatment of conditions mediated by crf
MXPA04002784A (en) Pharmaceutically acceptable salts of 20(s)-camptothecins.
CA2352332A1 (en) Hygromycin a derivatives
HRP20010845A9 (en) DERIVATIVES WITH CINAMOILAMINOALKYL OF SUBSTITUTED BENZENSULFONAMIDE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP